Welcome to our dedicated page for Reneo Pharmaceuticals SEC filings (Ticker: RPHM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RPHM SEC filings page on Stock Titan provides access to the regulatory record associated with Reneo Pharmaceuticals, Inc. and its subsequent transformation into OnKure Therapeutics, Inc. These filings trace the company’s evolution from a pharmaceutical issuer historically focused on rare genetic mitochondrial diseases to the public entity for a precision oncology business under the OnKure name and the OKUR ticker.
Historical Reneo filings include periodic reports and disclosures that describe its focus on therapies for patients with rare genetic mitochondrial diseases, such as primary mitochondrial myopathies (PMM), and its development of mavodelpar (REN001), a potent and selective PPARδ agonist. Investors can use these documents to understand the company’s former research programs, clinical strategy, and financial position leading up to the suspension of mavodelpar development and the initiation of a strategic alternatives process.
Later filings detail the merger with OnKure, Inc., including the registration statement and proxy materials referenced in company news releases. These documents explain the structure of the all-stock transaction, expected ownership percentages, conditions to closing, and the planned name and ticker change to OnKure Therapeutics, Inc. (OKUR). Post-merger, current reports on Form 8-K reference OnKure Therapeutics, Inc. as the registrant and note that Reneo Pharmaceuticals is a former name, reflecting the completed corporate transition.
On Stock Titan, users can review these SEC filings alongside AI-powered tools that help summarize lengthy documents and highlight key items such as business descriptions, risk factors, and material events. For the historical RPHM symbol, this page serves as a regulatory archive, while ongoing filings for the operating precision oncology company appear under the OnKure Therapeutics, Inc. name and the OKUR ticker.